How is one Chinese biotechnology group succeeding in supporting the earliest stage of new drug discovery when global pharmaceutical companies have given up? Dr Jun Mao, founder and chairwoman of Viva Ventures, explains how it leverages its in-house expertise to invest in hundreds of biotech startups in the $20 trillion global pharmaceutical and biotechnology market.
